Who Can Safely Discontinue Treatment in Myasthenia Gravis? Insights From a Long‐Term Real‐World Study

Key Points

• The research aims to identify safe criteria for discontinuing treatment in patients with myasthenia gravis.
• Long-term, real-world study design analyzed treatment discontinuation in myasthenia gravis patients.
• Assessments included age of onset, history of rituximab use, and treatment duration.
• Evaluation focused on relapse rates following treatment discontinuation.
• Discontinuation of treatment led to substantial relapse risks for patients with myasthenia gravis.
• Younger onset age and prior rituximab use influenced discontinuation success.
• Adequate treatment and consolidation duration are crucial for optimizing outcomes.